The future of resilience innovation will require all hands on deck. Photo via Getty Images

As Houstonians know more than most, a natural disaster can set a thriving city back millions. And, as it seems, these natural disasters aren't going anywhere. The question innovators, governments, insurance companies, and affected citizens keep asking is "what can be done?"

"Over the past decade we've been in and out of several disasters in the billions of dollars of impact," says Richard Seline, managing partner at ResilientH2O Partners. "But it's not without response."

Governments are deploying billions into fixing infrastructure, and Seline gathered risk mitigation experts for a conversation and startup pitch session as a part of Houston Tech Rodeo to discuss the future of this field. The experts weighed in on how risk mitigation and disaster prevention is going to need to be supported by both local and national governments.

Pamela Williams, executive director at BuildStrong Coalition, says she's been in the industry for decades now and has observed new financial support opportunities coming in at a federal level. These entities are looking for cost effective, risk reducing technologies. Innovators can think of these resources as seed funds — with a very high return on investment.

"Investments pre-disaster to draw down risk will save us … up to $11 for every $1 invested," she says on the panel. "Pre-disaster mitigation is where it's at."

And the solutions can't just come from one office within the national government — it needs to be a collaborative effort, she adds.

"We have got to provide flexibility, consistency — and truly be able to leverage all of these resources together so that we can do these transformational unthought of projects," Williams says.

Local governments are also tasked with increasing focus and funding on disaster prevention — maybe even more so than federal agencies, says Ron Prater, executive director at Big City Offices of Emergency Management.

"All disasters are local," he explains. "Locals have to be ready. ...Feds have money and resources but they aren't going to come in and save the day."

Governmental support is going to be needed to advance risk mitigation technology and innovation, but entrepreneurs might also have to seek aid elsewhere.

"While there are funds available for entrepreneurs and innovators, the fact is it will not always come from the government," Seline says. "There are billions of dollars of insurance, reinsurance, and non-traditional financing beginning to emerge — most of it centered around insuratech."

Williams says companies have a unique role to play in the continued conversation of driving these types of inventions.

"Our private sector partners have the ability to convene people," she says, "and bring perspectives to the table that have never before been there to come up with creative solutions."

Cultivating diverse thought leadership is crucial to the equation, says panel moderator Landi Spearman, generational and change management consultant at Organized Shift, who explains that Houston is an especially strategic place for this innovation to occur, since it's the most diverse big city in the country.

"When we think about resilience and people, we get to leverage our diversity of perspective. You get to bring yourself to the solution and you get to include others," she says.

There are a few types of exciting technologies emerging in resilience innovation — from finding ways to optimize and assist brokers and carriers as well as the equipment, technology, and data that's coming out of the public-private sector. One that interests Prater in particular is the opportunity to collect data.

"AI and machine learning are going to improve how (emergency managers) get situation awareness — how accurate it is and how timely it is," he says. "One of their main goals is to share as much information as possible."

The panel concluded with three startup pitches from NanoTech, a fireproofing and insulation product; IVPAir, a device that kills COVID-19 germs right from the air; and Climaguard, a weatherproofing invention to protect cars.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.